Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Larysa Sanchez, Ajai Chari, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Fei Huang, Dawn Marie Stull, Jonathan Dabora, Melanie Young, Stephen J. Noga, Selina Pi, Melody Zhang, Azeem Banatwala, Mei Sheng Duh, Sikander Ailawadhi
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States'. Together they form a unique fingerprint.